U 82208E | 136591-56-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: U 82208E
• 英文别名: N-(4-((1R)-4-(ethylheptylamino)-1-hydroxybutyl)phenyl)methanesulfonamide；N-[4-[(1R)-4-[ethyl(heptyl)amino]-1-hydroxybutyl]phenyl]methanesulfonamide
• CAS: 136591-56-5
• 化学式: C₂₀H₃₆N₂O₃S
• 分子量: 384.583
• InChiKey: ALOBUEHUHMBRLE-HXUWFJFHSA-N

物化性质

• 沸点：
  522.4±60.0 °C(Predicted)
• 密度：
  1.099±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  26
• 可旋转键数：
  14
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  78
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (R)-(-)-1-萘乙基异氰酸酯 、 U 82208E 在 N-甲基吡咯烷酮 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 以59 mg的产率得到
  参考文献：
  名称：

  Synthesis of (R)-N-[4-[4-(dibutylamino)-1-hydroxybutyl]phenyl]methanesulfonamide, (E)-2-butenedioate (2:1) salt (artilide fumarate) and the enantiomers of N-[4-[4-(ethylheptylamino)-1-hydroxybutyl]phenyl]methanesulfonamide, (E)-2-butenedioate (2:1) salt (ibutilide fumarate)

  摘要：

  Syntheses of artilide fumarate, its (S) enantiomer and the (R) and (S) enantiomers of ibutilide fumarate were achieved by reduction of the prochiral ketones with (+) and (-)-B-chlorodiisopinocampheylborane. Several methods for analyzing the optical purity of these compounds are presented. The absolute configurations were established by a single crystal X-ray crystallographic analysis of (S)-N-[4-[4-(dibutylamino)-1-hydroxy-4-oxobutyl]phenyl]methanesulfonamide. (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/0957-4166(96)00063-8
• 作为产物：
  描述：

  N-乙基-N-庚基-4-[(甲磺酰氨基)苯基]-4-氧代丁酰胺 在 lithium aluminium tetrahydride 、 (+)-二异松蒎基氯硼烷 作用下， 以 四氢呋喃 为溶剂， 反应 1.25h， 生成 U 82208E
  参考文献：
  名称：

  Synthesis of (R)-N-[4-[4-(dibutylamino)-1-hydroxybutyl]phenyl]methanesulfonamide, (E)-2-butenedioate (2:1) salt (artilide fumarate) and the enantiomers of N-[4-[4-(ethylheptylamino)-1-hydroxybutyl]phenyl]methanesulfonamide, (E)-2-butenedioate (2:1) salt (ibutilide fumarate)

  摘要：

  Syntheses of artilide fumarate, its (S) enantiomer and the (R) and (S) enantiomers of ibutilide fumarate were achieved by reduction of the prochiral ketones with (+) and (-)-B-chlorodiisopinocampheylborane. Several methods for analyzing the optical purity of these compounds are presented. The absolute configurations were established by a single crystal X-ray crystallographic analysis of (S)-N-[4-[4-(dibutylamino)-1-hydroxy-4-oxobutyl]phenyl]methanesulfonamide. (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/0957-4166(96)00063-8

文献信息

• CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY
  申请人：Cerulean Pharma Inc.

  公开号：US20130196906A1

  公开（公告）日：2013-08-01

  Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of a disease or disorder, e.g., autoimmune disease, inflammatory disease, central nervous system disorder, cardiovascular disease, or metabolic disorder. Also provided are CDP-therapeutic agent conjugates, particles comprising CDP-therapeutic agent conjugates, and compositions comprising CDP-therapeutic agent conjugates.

  提供了关于使用CDP-治疗剂偶联物治疗疾病或紊乱的方法，例如自身免疫疾病、炎症性疾病、中枢神经系统紊乱、心血管疾病或代谢紊乱。还提供了CDP-治疗剂偶联物、包含CDP-治疗剂偶联物的颗粒以及包含CDP-治疗剂偶联物的组合物。
• Heteroaryl compounds as P2Y1 receptor inhibitors
  申请人：Sutton C. James

  公开号：US20060173002A1

  公开（公告）日：2006-08-03

  The present invention provides novel heteroaryl compounds and analogues thereof, which are selective inhibitors of the human P2Y 1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y 1 receptor activity.

  本发明提供了新颖的杂环芳基化合物及其类似物，这些化合物是人类P2Y1受体的选择性抑制剂。该发明还提供了相应的各种药物组合物以及调节P2Y1受体活性治疗对其敏感的疾病的方法。
• [EN] PHOSPHORAMIDIC ACID PRODRUGS OF 5 - [5 - PHENYL- 4 - (PYRIDIN- 2 - YLMETHYLAMINO) QUINAZOLIN- 2 - YL] PYRIDINE- 3 - SULFONAMIDE<br/>[FR] PROMÉDICAMENTS D'ACIDE PHOSPHORAMIDIQUE DE 5-[5-PHÉNYL-4-(PYRIDIN-2-YLMÉTHYLAMINO)QUINAZOLIN-2-YLE]PYRIDINE-3-SULFONAMIDE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2013188254A1

  公开（公告）日：2013-12-19

  A compound of structural formula (I), wherein R is H or -PO3H or a pharmaceutically acceptable salt form thereof. The compounds are useful as inhibitors of potassium channel function and in the treatment and prevention of arrhythmia, IKur-associated disorders, and other disorders mediated by ion channel function.

  其中R是H或-PO3H或其药物可接受的盐形式的化合物结构式(I)。这些化合物作为钾通道功能的抑制剂，以及用于治疗和预防心律不齐、IKur相关疾病和其他由离子通道功能介导的疾病是有用的。
• [EN] BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS<br/>[FR] PRO-FRAGMENTS BIORÉVERSIBLES POUR MÉDICAMENTS CONTENANT DE L'AZOTE ET DE L'HYDROXYLE
  申请人：BAIKANG SUZHOU CO LTD

  公开号：WO2015081891A1

  公开（公告）日：2015-06-11

  Disclosed are promoieties of the following formula which can be used to form prodrugs of nitrogen-containing or hydroxyl-containing drug or a pharmaceutically active agent: (I) and pharmaceutical compositions comprising the prodrugs.

  披露了以下公式的促销性质，它们可用于形成含有氮或羟基的药物或药物活性剂的的前药：(I)以及包含这些前药的药物组合物。
• Water-Soluble Derivatives and Prodrugs of Acacetin and Methods of Making and Using Thereof
  申请人：Shanghai Institute of Pharmaceutical Industry

  公开号：US20150218193A1

  公开（公告）日：2015-08-06

  Water-soluble derivatives and/or prodrugs of acacetin are described herein. The compounds can be used as cardioprotection agents against myocardial infarction induced by ischemia-reperfusion. In one embodiment the compounds are used to treat ischemic cardiac diseases. In the preferred embodiment, the compounds are used to treat and/or prevent myocardial infarction in humans.

  水溶性阿克塞丁衍生物和/或前药在本发明中有所描述。这些化合物可用作针对由缺血-再灌注引起的心肌梗死的护心剂。在一个实施例中，这些化合物用于治疗缺血性心脏病。在优选的实施例中，这些化合物用于治疗和/或预防人类的心肌梗死。